BioMarin's gene therapy nabs accelerated review in U.S. for a rare metabolic disorder

• The FDA has designated Fast Track status to BioMarin Pharmaceutical's (NASDAQ:BMRN) BMN-307, an investigational gene therapy for the treatment of phenylketonuria.
• Both the FDA and European Medicines Agency have granted BMN 307 Orphan Drug tags.
• Last week, BioMarin dosed the first participant in Phearless Phase 1/2 study with BMN 307
• https://seekingalpha.com/news/3619391-biomarins-gene-therapy-nabs-accelerated-review-in-u-s-for-rare-metabolic-disorder